enzastaurin has been researched along with Central Nervous System Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, A; Blaney, SM; Boyett, JM; Chintagumpala, M; Decker, RL; Fouladi, M; Gilbertson, R; Goldman, S; Kilburn, LB; Kocak, M; Kun, L; Su, J; Wetmore, C | 1 |
| Stummer, W | 1 |
1 trial(s) available for enzastaurin and Central Nervous System Neoplasm
| Article | Year |
|---|---|
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Phosphorylation; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Treatment Outcome; Young Adult | 2015 |
1 other study(ies) available for enzastaurin and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Perspectives in central nervous system malignancies.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2006 |